Amplifying tumour antigen presentations from intratumourally entrapped dendritic cells
- 18 June 2026
- journal article
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (7) , 1048-1059
Abstract
Antigen presentation within solid tumours presents a significant clinical challenge for systemic immune activation. Although radiotherapy or chemotherapy can generate tumour antigens by destroying tumour cells, the insufficient number and impaired function of dendritic cells within solid tumours compromises effective antigen presentation. Here we present plant-derived nanoparticles coated with nanohydroxyapatite that promote dendritic cell activation and amplify the production of dendritic-cell-derived antigen-presenting vesicles in vivo through the modulation of intracellular immune conversion and calcium signalling. The technology, termed the intratumoural generation of immunopresentation vesicles after tumour exposure, enabled a dramatic enhancement in antigen presentation within lymph nodes and, consequently, boosted systemic immune response, exhibiting superior antitumour efficacy in multiple solid tumour models when combined with radiotherapy. This strategy of amplifying immunoreactive nanovesicle production in vivo may serve as a promising immunopotentiating platform, advancing various cancer treatments.Keywords
Funding Information
- National Natural Science Foundation of China (22577056)
This publication has 58 references indexed in Scilit:
- Plant‐Derived Vesicle‐Like Nanoparticles as Promising Biotherapeutic Tools: Present and FutureAdvanced Materials, 2023
- Plant‐derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applicationsJournal of Extracellular Vesicles, 2022
- Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironmentCell, 2022
- Development of a Cancer Vaccine Using In Vivo Click‐Chemistry‐Mediated Active Lymph Node Accumulation for Improved ImmunotherapyAdvanced Materials, 2021
- Visualizing Synaptic Transfer of Tumor Antigens among Dendritic CellsCancer Cell, 2020
- Extracellular vesicles for drug deliveryAdvanced Drug Delivery Reviews, 2016
- Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor SignalingCell Reports, 2015
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Dendritic cells dysfunction in tumour environmentCancer Letters, 2008